Recent Finacing
Recent Raise
Delix Therapeutics is a Boston-based preclinical neuroscience company developing non-hallucinogenic, small-molecule psychoplastogens that induce targeted neuroplasticity, advancing orally bioavailable candidates (e.g., DLX-1, DLX-7) through preclinical and pre-IND studies.
